82 related articles for article (PubMed ID: 30540597)
1. 68Ga-PSMA PET/CT Urachus Metastases in Recurrent Prostate Cancer With Very Low PSA Level.
Le Thiec M; Rusu D; Fleury V; Kraeber-Bodéré F; Rousseau C
Clin Nucl Med; 2019 Jan; 44(1):40-41. PubMed ID: 30540597
[TBL] [Abstract][Full Text] [Related]
2. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
3. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
4. Comparison of standard and delayed imaging to improve the detection rate of [
Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
[TBL] [Abstract][Full Text] [Related]
5. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
6. Rapidly Evolving Diffuse Omental Carcinomatosis of Prostate Cancer in 68Ga-PSMA PET/CT.
Hoberück S; Sommer U; Grey A; Hölscher T; Baretton GB; Kotzerke J
Clin Nucl Med; 2021 Apr; 46(4):e216-e217. PubMed ID: 33234924
[TBL] [Abstract][Full Text] [Related]
7. 18F-DCFPyL PET/CT in a Single Large Metastasis With Prostate-Specific Antigen Level of 856 ng/mL.
Wondergem M; Srbljin S; van der Zant FM; Broos WAM; Knol RJJ
Clin Nucl Med; 2019 Oct; 44(10):e588-e589. PubMed ID: 31274553
[TBL] [Abstract][Full Text] [Related]
8. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
9. Detection of Unusual Peritoneal Metastases of Prostate Cancer With 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Simsek DH; Sanli Y
Clin Nucl Med; 2020 Jan; 45(1):63-64. PubMed ID: 31789914
[TBL] [Abstract][Full Text] [Related]
10. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
11. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-PSMA PET/MR-Positive Peritoneal Metastasis in the Falciform Ligament in Recurrent Prostate Cancer.
Kranzbühler B; Tran S; Zilli T; Burger IA
Clin Nucl Med; 2017 Aug; 42(8):e388-e389. PubMed ID: 28590295
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
Bluemel C; Krebs M; Polat B; Linke F; Eiber M; Samnick S; Lapa C; Lassmann M; Riedmiller H; Czernin J; Rubello D; Bley T; Kropf S; Wester HJ; Buck AK; Herrmann K
Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008
[TBL] [Abstract][Full Text] [Related]
14. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of
Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
[TBL] [Abstract][Full Text] [Related]
16. Abdominal Splenosis Mimicking Peritoneal Metastasis in Prostate-Specific Membrane Antigen PET/CT, Confirmed With Selective Spleen SPECT/CT.
Demirci E; Has Simsek D; Kabasakal L; Mülazimoğlu M
Clin Nucl Med; 2017 Dec; 42(12):e504-e505. PubMed ID: 29076911
[TBL] [Abstract][Full Text] [Related]
17.
Sachpekidis C; Bäumer P; Kopka K; Hadaschik BA; Hohenfellner M; Kopp-Schneider A; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):904-912. PubMed ID: 29362859
[TBL] [Abstract][Full Text] [Related]
18. 68Ga-PSMA-11 PET/CT in a Case of Isolated Parietal Peritoneal Metastasis From Prostate Adenocarcinoma.
Zhao Q; Dong A; Zuo C
Clin Nucl Med; 2023 Oct; 48(10):913-914. PubMed ID: 37682611
[TBL] [Abstract][Full Text] [Related]
19. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.
De Bari B; Mazzola R; Aiello D; Fersino S; Gregucci F; Alongi P; Nicodemo M; Cavalleri S; Salgarello M; Alongi F
Radiol Med; 2018 Sep; 123(9):719-725. PubMed ID: 29687208
[TBL] [Abstract][Full Text] [Related]
20. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
